Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Tofacitinib tablet plus betamethasone cream: Tofacitinib tablet 5 mg 1 tablet twice daily after meal and 0.1% betamethasone valerate cream twice daily application to the affected area c
Sponsors
Bankura Sammilani Medical College
Eligibility
Inclusion criteria
Inclusion criteria: Patients with stable acral vitiligo of either sex and 18-60 years of age.
Exclusion criteria
Exclusion criteria: 1. Patients not giving consent 2. Pregnant and lactating women 3. Patient taking known photosensitizer drugs or immunosuppressive therapy. 4. Patients with neurological or psychiatric disorders. 5. Participation in any clinical trial within last 3 months. 6. Substance or alcohol use. 7. Known case of liver disease. 8. Immunocompromised patients and cancer patients receiving chemotherapy 9. Active or past history of tuberculosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study is conducted as superiority trial design with the research hypothesis of combined treatment of tofacitinib tablet and betamethasone cream is expected to be superior in terms of efficacy measured by vitiligo area scoring index in comparison with betamethasone cream alone.Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| a) To assess the tolerability and safety of tofacitinib tablet and betamethasone cream.Timepoint: 6 months;b) To assess the changes of vitiligo disease activity score and vitiligo impact scale-22 with the above mentioned regime.Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Aparesh Chandra Patra
Bankura Sammilani Medical College
Outcome results
None listed